公开(公告)号：KR100632697B1

公开(公告)日：2006-10-11

申请号：KR1020050048891

申请日：2005-06-08

Applicant: 한림제약(주)

Inventor： 정유섭 ,  하문천

IPC: C07D211/90

Abstract: 본 발명은 암로디핀 니코티네이트 결정성 2수화물의 제조방법에 관한 것이며, 본 발명의 암로디핀 니코티네이트 결정성 2수화물은 시판중인 암로디핀 베실레이트보다 그 약효가 월등히 우수하며, 물에 대한 용해도, 안정성, 비흡습성 및 정제제형으로의 가공성이 우수하다.
암로디핀 니코티네이트 결정성 2수화물

公开(公告)号：KR100476636B1

公开(公告)日：2005-03-17

申请号：KR1020020054808

申请日：2002-09-11

Applicant: 한림제약(주)

Inventor： 정유섭 ,  하문천

IPC: C07D211/90

CPC classification number: C07D211/90

Abstract: 본 발명은 L-(+)-타르트레이트를 이용하여 광학 이성질체 R-(+)-암로디핀을 제거하고 여액에 메틸렌클로라이드를 첨가하여 순수한 S-(-)-암로디핀 에난치오머를 분리하는 대단히 간편하고 경제적인 방법에 관한 것이다.

公开(公告)号：KR1020030081006A

公开(公告)日：2003-10-17

申请号：KR1020030001259

申请日：2003-01-09

Applicant: 한림제약(주)

Inventor： 정유섭 ,  하문천

IPC: C07D211/90

Abstract: PURPOSE: Amlodipine nicotinate and a preparation process thereof are provided, which amlodipine nicotinate has improved medical efficacy, water solubility, stability, nonabsorption, etc. CONSTITUTION: An amlodipine nicotinate anhydride or hydride is provided, wherein the amlodipine nicotinate hydride has XRD pattern of figure 6. A process for preparing amlodipine nicotinate anhydride or hydride comprises reacting amlodipine with nicotinate in water-containing inert solvent, wherein 95% methanol-isopropanol or water-isopropanol(5:95) mixed solvent are used for recrystallization of the amlodipine nicotinate anhydride or hydride. The amlodipine nicotinate anhydride is prepared by drying an amlodipine nicotinate hydride under reduced pressure at 115 to 125 deg. C.

Abstract translation: 目的：提供氨氯地平烟酸酯及其制备方法，其中氨氯地平烟碱具有改善的药效，水溶性，稳定性，不吸收等。组成：提供氨氯地平烟酸酐或氢化物，其中氨氯地平烟酸氢化物具有图的XRD图 6.制备氨氯地平烟酸酐或氢化物的方法包括在含水惰性溶剂中使氨氯地平与烟酸酯反应，其中使用95％甲醇 - 异丙醇或水 - 异丙醇（5:95）混合溶剂重结晶氨氯地平烟酸酐酸酐或 氢化物。 氨氯地平烟酸酐通过在115至125℃的减压下干燥氨氯地平烟酸氢化物来制备。 C。

公开(公告)号：KR1020010066897A

公开(公告)日：2001-07-11

申请号：KR1020000038051

申请日：2000-07-04

Applicant: 한림제약(주)

Inventor： 김재신 ,  정유섭

IPC: C01B25/45

CPC classification number: C07F9/3873 ,  C01B25/45 ,  C07F9/38

Abstract: PURPOSE: A crystalline pamidronic acid disodium salt hydrate is provided, which has excellent storability and is easily processed to a preparation for oral administration. And a method for preparing thereof is also provided. CONSTITUTION: The crystalline pamidronic acid disodium salt hydrate has a water content of 17.0-20.0% and is a mixture form of pamidronic acid disodium salt trihydrate and pamidronic acid disodium salt tetrahydrate. The hydrate is represented by the following formula (1), wherein x is 3 or 4. The method comprises steps of: (i) neutralizing pamidronic acid and sodium hydroxide between pH 7.5-8.5; (ii) after filtering the produced insoluble material of the step (i), adding isopropanol to the filtrate to form a salt; (iii) after dissolving the obtained salt in water, leaving it at room temperature to crystallize it; (iv) cooling and filtering the crystallized solution of the step (iii) to obtain a crystal; and (v) drying the obtained crystal at a temperature of 75-85 deg.C under atmospheric pressure.

Abstract translation: 目的：提供结晶的帕米膦酸二钠盐水合物，其具有优异的储存性，并且易于加工成口服制剂。 还提供了其制备方法。 构成：结晶的帕米膦酸二钠盐水合物的水含量为17.0-20.0％，是一种混合形式的帕米膦酸二钠盐三水合物和帕米膦酸二钠盐四水合物。 水合物由下式（1）表示，其中x为3或4.该方法包括以下步骤：（i）在pH 7.5-8.5之间中和帕米膦酸和氢氧化钠; （ii）在过滤所产生的步骤（i）的不溶物质之后，向滤液中加入异丙醇形成盐; （iii）将得到的盐溶于水中后，将其在室温下使其结晶; （iv）冷却并过滤步骤（iii）的结晶溶液以获得晶体; 和（v）在大气压下在75-85℃的温度下干燥所得晶体。